Security
Revolution Medicines, Inc. Warrant · RVMDW
RVMDWNASDAQWarrantCurrentCIK 1628171Updated Nov 6, 2026
RVMDW price & chart
Loading TradingView…
NASDAQ:RVMDW on TradingView ↗About the company
Revolution Medicines is a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide. For more information, visit www.revmed.com and follow Revolution Medicines on LinkedIn, X (Twitter) and Instagram.
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A - filed by FMR LLC regarding Revolution Medicines, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Other Events
Items 2.03, 8.01
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,251,920,000Source | 1,762,999,000Source | 4,323,270,000Source | 2,429,568,000Source | 1,808,437,000Source | 2,253,737,000Source | 2,365,353,000Source | 1,908,362,000Source | 2,354,508,000Source | 2,558,301,000Source | 2,061,705,000Source | 811,930,000Source |
| Property, Plant and Equipment, NetUSD | 32,926,000Source | 24,814,000Source | 34,608,000Source | 33,049,000Source | 25,284,000Source | 31,475,000Source | 27,153,000Source | 23,697,000Source | 33,194,000Source | 24,289,000Source | 22,865,000Source | 18,659,000Source |
| GoodwillUSD | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 55,869,000Source | 56,937,000Source | 55,800,000Source | 56,136,000Source | 57,205,000Source | 55,800,000Source | 56,403,000Source | 57,472,000Source | 55,800,000Source | 56,670,000Source | 57,739,000Source | 58,807,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 217,442,000Source | 201,262,000Source | 815,435,000Source | 402,438,000Source | 275,713,000Source | 440,939,000Source | 333,554,000Source | 288,432,000Source | 383,745,000Source | 543,064,000Source | 696,148,000Source | 161,412,000Source |
| Assets, CurrentUSD | 1,977,489,000Source | 1,579,139,000Source | 4,028,338,000Source | 2,176,439,000Source | 1,624,730,000Source | 1,967,913,000Source | 2,134,582,000Source | 1,729,202,000Source | 2,075,037,000Source | 2,327,632,000Source | 1,879,281,000Source | 660,185,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 45,981,000Source | 29,658,000Source | 90,369,000Source | 39,268,000Source | 34,015,000Source | 59,829,000Source | 31,907,000Source | 25,662,000Source | 49,358,000Source | 38,333,000Source | 25,072,000Source | 10,569,000Source |
| Operating Lease, Right-of-Use AssetUSD | 134,450,000Source | 74,338,000Source | 127,844,000Source | 114,000,000Source | 75,305,000Source | 129,895,000Source | 115,777,000Source | 76,193,000Source | 132,084,000Source | 117,534,000Source | 77,149,000Source | 55,077,000Source |
| Other Assets, NoncurrentUSD | 14,869,000Source | 10,275,000Source | 14,760,000Source | 31,420,000Source | 8,274,000Source | 14,479,000Source | 13,132,000Source | 4,159,000Source | 14,779,000Source | 13,870,000Source | 7,032,000Source | 2,857,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 655,016,000Source | 196,695,000Source | 1,717,032,000Source | 564,199,000Source | 189,589,000Source | 753,820,000Source | 287,203,000Source | 182,895,000Source | 723,211,000Source | 293,097,000Source | 235,511,000Source | 126,742,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 18,000Source | 16,000Source | 21,000Source | 18,000Source | 16,000Source | 19,000Source | 18,000Source | 16,000Source | 19,000Source | 18,000Source | 16,000Source | 9,000Source |
| Retained Earnings (Accumulated Deficit)USD | -2,504,210,000Source | -1,543,232,000Source | -3,967,289,000Source | -2,199,004,000Source | -1,386,944,000Source | -3,322,918,000Source | -1,951,217,000Source | -1,253,711,000Source | -2,869,102,000Source | -1,737,801,000Source | -1,137,708,000Source | -701,341,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 3,116,000Source | 3,812,000Source | -5,950,000Source | 1,302,000Source | -1,863,000Source | -622,000Source | 1,707,000Source | -1,198,000Source | 3,237,000Source | 1,321,000Source | 544,000Source | -1,780,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,596,904,000Source | 1,566,304,000Source | 2,606,238,000Source | 1,865,369,000Source | 1,618,848,000Source | 1,499,917,000Source | 2,078,150,000Source | 1,725,467,000Source | 1,631,297,000Source | 2,265,204,000Source | 1,826,194,000Source | 685,188,000Source |
| Additional Paid in Capital, Common StockUSD | 4,097,980,000Source | 3,105,708,000Source | 6,579,456,000Source | 4,063,053,000Source | 3,007,639,000Source | 4,823,438,000Source | 4,027,642,000Source | 2,980,360,000Source | 4,497,143,000Source | 4,001,666,000Source | 2,963,342,000Source | 1,388,300,000Source |
| Liabilities and EquityUSD | 2,251,920,000Source | 1,762,999,000Source | 4,323,270,000Source | 2,429,568,000Source | 1,808,437,000Source | 2,253,737,000Source | 2,365,353,000Source | 1,908,362,000Source | 2,354,508,000Source | 2,558,301,000Source | 2,061,705,000Source | 811,930,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 245,622,000Source | 110,863,000Source | 354,061,000Source | 184,534,000Source | 105,332,000Source | 289,599,000Source | 158,599,000Source | 93,723,000Source | 290,424,000Source | 163,914,000Source | 143,851,000Source | 61,984,000Source |
| Operating Lease, Liability, CurrentUSD | 16,326,000Source | 8,396,000Source | 16,753,000Source | 13,088,000Source | 8,332,000Source | 16,610,000Source | 12,979,000Source | 8,169,000Source | 16,468,000Source | 12,872,000Source | 7,369,000Source | 6,773,000Source |
| Accounts Payable, CurrentUSD | 74,849,000Source | 24,456,000Source | 88,419,000Source | 56,761,000Source | 29,319,000Source | 80,538,000Source | 47,507,000Source | 32,379,000Source | 64,616,000Source | 54,427,000Source | 61,788,000Source | 21,306,000Source |
| Operating Lease, Liability, NoncurrentUSD | 142,135,000Source | 78,310,000Source | 137,741,000Source | 119,699,000Source | 79,079,000Source | 140,019,000Source | 121,363,000Source | 79,860,000Source | 142,234,000Source | 122,971,000Source | 80,575,000Source | 57,432,000Source |
| Deferred Income Tax Liabilities, NetUSD | 2,353,000Source | 3,115,000Source | 2,353,000Source | 2,353,000Source | 3,115,000Source | 2,353,000Source | 2,353,000Source | 3,115,000Source | 2,353,000Source | 2,353,000Source | 3,115,000Source | 7,025,000Source |
| Other Liabilities, NoncurrentUSD | 2,479,000Source | 1,644,000Source | 1,648,000Source | 7,204,000Source | 656,000Source | 6,879,000Source | 4,138,000Source | 3,040,000Source | 1,208,000Source | 670,000Source | 1,458,000Source | 301,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 5,000,000Source | — | — | — | — | 5,000,000Source | — | — | 5,000,000Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,353,000Source | 2,353,000Source | 3,115,000Source | 7,025,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -453,816,000Source | -213,416,000Source | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | 5,000,000Source | 3,972,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 87,299,000Source | 25,084,000Source | 118,389,000Source | 79,197,000Source | 61,772,000Source | 31,196,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | 0Source | 0Source | -1,254,000Source | -3,419,000Source | -1,256,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 16,857,000Source | -8,270,000Source | 9,535,000Source | -6,465,000Source | 32,469,000Source | 7,288,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | -738,000Source | -3,848,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -354,165,000Source | -194,435,000Source | -897,741,000Source | -557,436,000Source | -350,572,000Source | -224,401,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 172,615,000Source | -15,949,000Source | 118,058,000Source | -554,394,000Source | -342,598,000Source | -24,116,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,538,000Source | 3,266,000Source | 15,990,000Source | 10,308,000Source | 7,729,000Source | 10,816,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 4,026,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 238,744,000Source | 874,000Source | 621,524,000Source | 959,413,000Source | 1,229,200,000Source | 301,432,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 57,194,000Source | -209,510,000Source | -158,159,000Source | -152,417,000Source | 536,030,000Source | 52,915,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 222,300,000Source | 204,150,000Source | 820,293,000Source | 406,354,000Source | 445,797,000Source | 337,252,000Source | 388,603,000Source | 546,762,000Source | 699,179,000Source | 163,149,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 30,779,000Source | 20,775,000Source | 67,000,000Source | 28,830,000Source | 87,299,000Source | 25,084,000Source | 118,389,000Source | 79,197,000Source | 61,772,000Source | 31,196,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | 237,000Source | — | 541,000Source | — | — | — |
| Amortization of Intangible AssetsUSD | — | — | 300,000Source | 300,000Source | 0Source | 300,000Source | 0Source | 267,000Source | 870,000Source | 1,069,000Source | 1,068,000Source | 1,069,000Source |
| DepreciationUSD | — | — | 2,000,000Source | 1,600,000Source | 2,100,000Source | 1,700,000Source | 2,200,000Source | 1,600,000Source | 7,400,000Source | 6,200,000Source | 5,042,000Source | — |
| Depreciation, Amortization and Accretion, NetUSD | — | — | — | — | — | — | 2,346,000Source | 1,692,000Source | 7,780,000Source | 6,559,000Source | — | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | 0Source | -32,000Source | -118,000Source | -52,000Source | -19,000Source |
| General and Administrative ExpenseUSD | — | — | 52,763,000Source | 23,960,000Source | 110,213,000Source | 40,580,000Source | 101,252,000Source | 35,011,000Source | 195,037,000Source | 97,299,000Source | 75,621,000Source | 40,586,000Source |
| GoodwillUSD | — | — | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source | 14,608,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | -753,000Source | -3,524,000Source | -420,000Source |
| InterestExpenseNonoperatingUSD | — | — | 11,428,000Source | 0Source | 23,781,000Source | 867,000Source | 12,197,000Source | 0Source | 24,231,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 22,083,000Source | 20,411,000Source | 35,579,000Source | 22,404,000Source | 19,508,000Source | 24,915,000Source | 90,694,000Source | 86,883,000Source | 47,482,000Source | 9,154,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -305,206,000Source | -156,288,000Source | -644,371,000Source | -247,787,000Source | -453,816,000Source | -213,416,000Source | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -305,206,000Source | -156,288,000Source | -644,371,000Source | -247,787,000Source | -453,816,000Source | -213,416,000Source | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Nonoperating Income (Expense)USD | — | — | 10,063,000Source | 19,424,000Source | -139,239,000Source | 16,927,000Source | -8,594,000Source | 27,344,000Source | 51,068,000Source | 88,678,000Source | 47,294,000Source | 9,154,000Source |
| Operating ExpensesUSD | — | — | 315,269,000Source | 175,712,000Source | 505,132,000Source | 264,714,000Source | 445,222,000Source | 240,760,000Source | 1,182,369,000Source | 689,524,000Source | 498,765,000Source | 293,659,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 0Source | 727,620,000Source | 323,706,000Source | 248,126,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 21,134,000Source | — | — | — |
| Other Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | 0Source | — | — | — | — | 0Source | 0Source | 11,580,000Source | 35,380,000Source |
| Operating Income (Loss)USD | — | — | -315,269,000Source | -175,712,000Source | -505,132,000Source | -264,714,000Source | -445,222,000Source | -240,760,000Source | -1,182,369,000Source | -689,524,000Source | -487,185,000Source | -258,279,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -305,206,000Source | -156,288,000Source | -644,371,000Source | -247,787,000Source | -453,816,000Source | -213,416,000Source | -1,131,301,000Source | -600,846,000Source | -439,891,000Source | -249,125,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | 0Source | — | — | — | — | 0Source | -753,000Source | -3,524,000Source | -420,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -305,206,000Source | -156,288,000Source | -644,371,000Source | -247,787,000Source | -453,816,000Source | -213,416,000Source | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.61Source | -0.94Source | -3.06Source | -1.31Source | -2.29Source | -1.13Source | -5.95Source | -3.58Source | -3.86Source | -3.08Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.61Source | -0.94Source | -3.06Source | -1.31Source | -2.29Source | -1.13Source | -5.95Source | -3.58Source | -3.86Source | -3.08Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 189,231,562Source | 166,843,984Source | 210,893,604Source | 188,583,288Source | 198,098,047Source | 188,145,904Source | 190,129,154Source | 167,737,672Source | 113,149,869Source | 80,626,525Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 189,231,562Source | 166,843,984Source | 210,893,604Source | 188,583,288Source | 198,098,047Source | 188,145,904Source | 190,129,154Source | 167,737,672Source | 113,149,869Source | 80,626,525Source |
| Interest Expense (non-operating)USD | — | — | 11,428,000Source | 0Source | 23,781,000Source | 867,000Source | 12,197,000Source | 0Source | 24,231,000Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 300,000Source | 300,000Source | 0Source | 300,000Source | 0Source | 267,000Source | 870,000Source | 1,069,000Source | 1,068,000Source | 1,069,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | -15,000Source | 324,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | — | — | — | — | 5,000,000Source | 4,000,000Source |
| General and Administrative ExpenseUSD | — | — | 52,763,000Source | 23,960,000Source | 110,213,000Source | 40,580,000Source | 101,252,000Source | 35,011,000Source | 195,037,000Source | 97,299,000Source | 75,621,000Source | 40,586,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -1,131,301,000Source | — | — | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Investment Income, InterestUSD | — | — | 22,083,000Source | 20,411,000Source | 35,579,000Source | 22,404,000Source | 19,508,000Source | 24,915,000Source | 90,694,000Source | 86,883,000Source | 47,482,000Source | 9,154,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -305,206,000Source | -156,288,000Source | -644,371,000Source | -247,787,000Source | -453,816,000Source | -213,416,000Source | -1,131,301,000Source | -600,093,000Source | -436,367,000Source | -248,705,000Source |
| Nonoperating Income (Expense)USD | — | — | 10,063,000Source | 19,424,000Source | -139,239,000Source | 16,927,000Source | -8,594,000Source | 27,344,000Source | 51,068,000Source | 88,678,000Source | 47,294,000Source | 9,154,000Source |
| Operating ExpensesUSD | — | — | 315,269,000Source | 175,712,000Source | 505,132,000Source | 264,714,000Source | 445,222,000Source | 240,760,000Source | 1,182,369,000Source | 689,524,000Source | 498,765,000Source | 293,659,000Source |
| Research and Development ExpenseUSD | — | — | 262,506,000Source | 151,752,000Source | 394,919,000Source | 224,134,000Source | 343,970,000Source | 205,749,000Source | 987,332,000Source | 592,225,000Source | 423,144,000Source | 253,073,000Source |
| Other Nonoperating Income (Expense) | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Filing attachments
rvmd-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress · Received U.S. FDA approval and launched RASONQUE® (daraxonrasib) for adult patients with metastatic pancreatic cancer who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy · Reported RASONQUE net product revenue of $198 million for the quarter, reflecting a partial quarter of sales following its U.S. commercial launch · …
Read attachment ↗rvmd-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 rvmd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress · U.S. FDA accepted daraxonrasib New Drug Application for review for previously treated metastatic pancreatic cancer following unprecedented Phase 3 RASolute 302 results · Rapidly implemented U.S. Expanded Access Program for eligible patients with previously treated metastatic pancreatic cancer · Achieved U.S. commercial launch rea…
Read attachment ↗rvmd-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 rvmd-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress · Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation · RASolute 302 data planned for submission to global regulatory authorities, including the U.S. Food and Drug Administrati…
Read attachment ↗d19920dex41.htm · 8-K · 2026-04-17
EX-4.1 3 d19920dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 REVOLUTION MEDICINES, INC. INDENTURE Dated as of April 17, 2026 U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. …
Read attachment ↗d19920dex42.htm · 8-K · 2026-04-17
EX-4.2 4 d19920dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 REVOLUTION MEDICINES, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of April 17, 2026 0.50% Convertible Senior Notes due 2033 CROSS REFERENCE TABLE* Trust Indenture Indenture Section Act Section 310 (a)(1) 10.09 (a)(2) 10.09 (a)(3) N/A (a)(4) …
Read attachment ↗